Psyence Group Inc. files Q2 Unaudited Condensed Consolidated Interim Financial Statements and MD&A
TORONTO, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science
biotechnology company with a focus on natural psychedelics in mental health and well-being, announces that the Unaudited Condensed Consolidated Interim Financial Statements for the six months
period ended September 30, 2021 and Management Discussion & Analysis (“MD&A”) for the three months ended September 30, 2021 will be filed on November 29, 2021.
As a result of a continuous disclosure review conducted by Staff of the Ontario Securities Commission, the Company has included enhanced disclosure in its MD&A relating to, among other things, liquidity and cash resources, discussion of operations, its projects, expenditures made, and the timing and costs anticipated to advance the Company's projects to the next stage. The Company has also enhanced its disclosure regarding the regulatory framework relating to psychedelic substances in each jurisdiction where the Company operates.
The Company has also filed its management information circular dated November 18, 2021 which includes the executive compensation disclosure required by Form 51-102F6V, Statement of Executive Compensation, which was not previously filed.
ABOUT PSYENCE GROUP: www.psyence.com
Psyence is a public life science biotechnology company listed on the Canadian Securities Exchange and (CSE: PSYG) and quoted on the OTCQB (OTCQB: PSYGF), with a focus on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.
Our name “Psyence” combines the words psychedelic and science to affirm our commitment to producing psychedelic medicines developed through evidence-based research.
Informed by nature and guided by science, we built and operate one of the world’s first federally licensed commercial psilocybin mushroom cultivation and production facilities.
Our team brings international experience in both business and science and includes experts in mycology, neurology, palliative care, and drug development. We work to develop advanced natural psilocybin products for clinical research and development. We have entered into a long term joint venture to launch mushroom-based mental wellness focused nutraceutical products, the GOODMIND collection, to support improved focus, calm, and sleep.